IMPACT REPORT 2023

THE KCA IS...

- Full of Impact
- Supporting and Empowering Patients
- Igniting our Global Community
- Heating Research Toward a Cure
- Uniting Healthcare Providers
THE KCA IS Full of Impact

- **316** Virtual Patient Symposium participants
  - 15 countries • 40 states

- **$50M** in federal kidney cancer research funding
- **16K** was distributed via the KCA’s Patient Assistance Fund to 63 people with $250 gift cards

- **20** support group meetings

- **25** Countries

- **794** Participants

- **1,495** Just Diagnosed Toolkits distributed

- **179 + 612 = $111,307**
  - participants
  - donors
  - raised

- **475** patients/caregivers assisted through the Patient Navigator Program

- **2,465** patients impacted through KCA resources
In March, for Kidney Cancer Awareness Month, you made your cities #OrangeUp! 25 cities illuminated orange to spread awareness and the need for more research in kidney cancer.

1. Little Rock, AR
   Union Plaza Building
   March 1
2. Gilbert, AZ
   Water Tower Plaza
   March 4
3. San Diego, CA
   Convention Center
   March 4
4. Denver, CO
   Wynkoop Walkway
   March 1–5
5. Hartford, CT
   The Stilts Building
   March 1–31
6. Jacksonville, FL
   Acosta Bridge
   March 4–8
7. Orlando, FL
   The Wheel at ICON Park
   March 11
8. Davenport, IA
   Davenport Bridge
   March 6–12
9. Chicago, IL
   BCBS Tower
   March 8
10. South Bend, IN
    River Lights Plaza
    March 4
11. Boston, MA
    City Hall
    March 4
12. Baltimore, MD
    City Hall Dome
    March 1–3
13. Minneapolis, MN
    I-35 W. St. Anthony Falls
    Bridge
    March 4
14. Charlotte, NC
    Wells Fargo
    March 4
15. Omaha, NE
    Fred and Pamela Buffett Cancer Center
    March 3–15
16. Concord, NH
    The Hotel Concord
    March 4
17. Highland, NY
    Mid-Hudson Bridge
    March 6
18. Cleveland, OH
    Terminal Tower
    March 4
19. Harrisburg, PA
    City Hall Dome
    March 3–5
20. Pittsburgh, PA
    Gulf Tower and Koppers Building
    March 4
21. Nashville, TN
    Korean War Veterans Memorial
    March 4
22. Sugar Land, TX
    Sugar Land Town Square
    March 5–10
23. Houston, TX
    Montrose Bridges and City Hall
    March 29–31
24. Austin, TX
    Fairmont Austin and Circuit of the Americas
    March 4
25. Queenston, Ontario, Canada
    Arthur Schmon Tower
    March 1
In 2023, we awarded six innovative researchers a total of $412,500 in research funding. In the past five years, we have impacted 32 research projects for a total of $4.9 million.

**KCA TRAILBLAZER AWARD**

Maria Carlo, MD, Memorial Sloan Kettering Cancer Center  
*Role of germline and somatic variants in NRF2 pathway genes in renal cell carcinoma*

Rana McKay, MD, UC San Diego  
*Dissecting predictors of response to immunotherapy in patients with renal cell carcinoma*

**CHROMOPHOBEC RCC FOCUS AWARD**

Niki Zacharias Millward, PhD, MD Anderson Cancer Center  
*Leveraging patient-derived xenograft models to identify and therapeutically target metabolic hallmarks of chromophobe renal cell carcinoma*

**TRANSLOCATION RCC FOCUS AWARD**  
in partnership with Joey’s Wings Foundation

Prateek Khanna, MD, Dana-Farber Cancer Institute  
*Therapeutic targeting of cell surface antigens in translocation renal cell carcinoma*

**INTERDISCIPLINARY RCC FOCUS AWARD**  
supported by the Michael and Ina Korek Foundation Trust

Brendan Guercio, MD, University of Rochester Medical Center  
*Associations of diet with the gut microbiome among patients with advanced/metastatic RCC receiving immune checkpoint inhibition*

**UNCLASSIFIED/PAPILLARY RCC FOCUS AWARD**  
supported by Brandon Butera and Maggie Valdes

Shinji Ohtake, MD, UCLA School of Medicine  
*Development of Models of NF2 loss in papillary and unclassified variant of kidney cancer*
Dr. Prateek Khanna received a 2023 KCA Translocation RCC Focus Award for research on “Therapeutic targeting of cell surface antigens in translocation renal cell carcinoma.” This award was given in partnership with Joey’s Wings Foundation, a KCA Affiliate Partner. Dr. Khanna is a Hematology/Oncology Fellow at the Dana-Farber Cancer Institute in Boston, Massachusetts. We spoke with Dr. Khanna about his research and the impact it can have on people with kidney cancer.

**Research Project Summary**

Translocation renal cell carcinoma (tRCC) is a rare but aggressive subtype of kidney cancer that constitutes 50% of pediatric and 5% of adult kidney cancer. tRCC is treated with therapies that were developed and tested for other subtypes of kidney cancer and are usually not very effective in tRCC. In this project, we aim to develop a treatment for tRCC directed against a molecular target unique to cell surface of tRCC. This idea is rooted in previous research done by his mentor—Dr. Srinivas Viswanathan (2022 KCA Trailblazer Award recipient)—who identified a surface molecule expressed uniquely in tRCC cells. Dr. Khanna now aims to develop a therapy that engages patients’ own immune T cells to recognize tRCC cancer cells, thereby causing immune mediated cancer cell death.

tRCC is a rare subtype of kidney cancer that was first classified by the WHO as a unique subtype of RCC in 2004. Since then, we have discovered that the biology of tRCC is driven by chromosomal translocations unique to this type of kidney cancer. However, we need to understand in more detail how these chromosomal abnormalities contribute to malignant biology of tRCC and identify potential drug targets. In the meantime, a cell surface-based therapy holds promise since these therapies are based on immune cell biology and have been shown to be beneficial in other cancer types.

The proposed cell surface therapy holds potential as first targeted treatment specifically for tRCC patients. Dr. Khanna is excited about the potential this project has. If we are successful, the treatment could quickly be brought to clinical trials and help patients. It is also a proof of concept to identify more cell surface targets in tRCC and other kidney subtypes, allowing us to develop a depth of targeted therapies for our patients.
Annamaria Scaccia was diagnosed with kidney cancer in 2020. She is a KCA Ambassador and certified fitness and nutrition coach who helps kidney cancer survivors optimize their performance without sacrificing their health.

Annamaria didn’t know it at the time, but when she was diagnosed with kidney cancer in late 2020, her dreams of being an amateur Muay Thai fighter would later shatter. Her urologist hoped to perform a partial nephrectomy, but after cutting into her body and seeing the tumor’s location on her left kidney, the urologist decided the whole organ had to go. This meant she couldn’t fight in any ring. She traded her gloves for weights and dove headfirst into the world of natural bodybuilding, competing in her first show back in November 2021.

She has been very open and honest about her story on social media, and over the last 2.5 years, she’s had several kidney cancer survivors, as well as people with kidney health issues, reach out to her to learn more about her story. They told her that they would “love to be a bodybuilder,” but now they “can’t” because they’ve lost a kidney. They recount stories of coaches and doctors who tell them they could never compete again because they can’t eat all the protein in the world. And with every conversation, her response was always the same:

“I didn’t become a bodybuilder until after I lost my left kidney—and until after my protein intake was cut considerably.”

Being a one-kidney bodybuilder is not easy. Bodybuilding is a humbling sport in and of itself, but when you’ve had a kidney removed, it can feel completely intimidating. Bulking is even slower, nutrition is even harder, and you long for protein fiercely. Where other natural bodybuilders may knock out five shows in a year, you may only be able to compete in two, because you need to be cognizant of putting too much strain on your remaining kidney. Not to mention all the mindset work you need to do to heal, both from the trauma of cancer and how that cancer has altered your body and entire life. Dealing with scanixety in the middle of prep magnifies the stress of the experience.
But even with the added challenges, it is possible to be a bodybuilder with one kidney. It takes honesty, diligence, resilience, time, and intention.

This past year, Annamaria joined the KCA’s Patient & Caregiver Advisory Council (PCAC). She was motivated to get involved because joining the council felt like a natural progression from her advocacy work as a KCA Ambassador. From her early days of survivorship, she focused her advocacy work primarily on nutrition and fitness. As a one-kidney bodybuilder, she couldn’t find any real, meaningful information on how to adjust her active lifestyle to her new reality. As a fitness and nutrition coach, she’s worked hard to close the gap by providing information, support, and guidance to fitness enthusiasts with kidney health concerns. As a member of the KCA’s PCAC, she knows she can continue this mission by teaming up with experts to create science-backed, publicly available resources tailored to patients and survivors interested in fitness and nutrition.

“Just wanting to thank you for all the effort you put into getting me assistance. It’s greatly appreciated and actually hard to believe that there are still people in today’s society that truly will go above and beyond to get others help these days. Without your help and calls, it wouldn’t have been possible for me to have received this. You are truly an angel.”

–Patient Assistance Fund Recipient

KCA’s Patient Resources

Patient Navigator Program
Just Diagnosed Toolkit
Financial Assistance
KCA Support Groups
Clinical Trial Finder
Patient Video Library
Virtual Patient Symposium
KCA Ambassador Program
Side Effects Tracker
Oncology Nurse Consultant
Ask INA® The Virtual Nutritionist
Smart Patients Online Community
Uniting Together  
Healthcare Providers

THE KCA NICHOLAS J. VOGELZANG HUMANITARIAN AWARD

This inaugural Award is presented to the late Dr. Nicholas J. Vogelzang, co-founder and long-serving board member of the KCA. It recognizes an individual who has made great impact in highlighting kidney cancer advocacy and made strides to raise awareness and resources to advance kidney cancer treatment and patient care. The KCA became a reality around Dr. Vogelzang’s kitchen table in 1990, and he remained a dynamic and steadfast supporter of the organization and its mission throughout his life. As one of the few oncologists working on kidney cancer at the time, Dr. Vogelzang was a beacon for those who were otherwise offered few choices and little hope for their diagnosis. His care and medical prowess helped countless patients and families, and his advocacy will help countless more. Dr. Vogelzang died on September 20, 2022.

“Nick was the reason I went into GU Oncology. His energy, charisma, and staunch patient advocacy drew me to him and this specialty. He has arguably had the greatest impact on kidney cancer of anyone, considering his academic accomplishments, mentoring, and co-founding of KCA. Many renal cell carcinoma (RCC) researchers, including myself, owe our success in RCC and contributions in patient care to Nick. I spoke with Nick on the phone and promised him we would keep fighting for better treatments for RCC.”

—Dr. Brian Rini, member of the KCA’s Medical Steering Committee and Professor of Medicine at the Vanderbilt-Ingram Cancer Center

“I got to know Nick when I joined the KCA’s board back in 2000. He was very helpful in choosing which direction the KCA was taking and how we should manage the Association, how we would be able to grow it. I recommended a couple of patients to him in the last few years. He was a great director, very easy to get to know, and I have a lot of respect for him.”

—William Perry, kidney cancer patient and member of the KCA’s Board of Directors from 2000–2021
Vogelzang spoke often about the importance of putting key resources into the hands of patients and providers alike, knowing that they must work together to solve problems. His work with the KCA to put these ideas into practice was a natural extension of his clinical practice and his personal values.

“My dad was a pastor and my mom a teacher, so service to others was a big part of my family. Church was a big part of our lives, academic excellence was strongly emphasized, and curiosity was always encouraged. My siblings and I share a deep commitment to service to others,” Vogelzang said, prior to his retirement from the KCA’s Board of Directors. “I have great pride in what the KCA has accomplished thus far, and though I know our important work is not over, I have great hope for the future. The KCA will remain a trusted resource that I’ll continue to share with my own patients and fellow medical professionals, and it will always hold a special place in my heart.”

NEW HEALTHCARE PROVIDER PROGRAM LAUNCHED
Women in RCC empowers and elevates female physicians in kidney cancer to lead and succeed through trainings, mentorship, open forums, and camaraderie. The KCA is proud to be a leader in bringing these woman together.

IMPACTFUL FAST FACTS: INTERNATIONAL KIDNEY CANCER SYMPOSIUM (IKCS) EUROPE AND NORTH AMERICA

<table>
<thead>
<tr>
<th>89 abstract submissions</th>
<th>82 posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 oral abstracts presented</td>
<td>796 total registrants</td>
</tr>
<tr>
<td>117 faculty presented</td>
<td></td>
</tr>
</tbody>
</table>
THE KCA IS

Igniting our Global Community

In 2023 we awarded 6 innovative researchers a total of $412,500 in research funding.

In the past 5 years we have impacted 32 patients, share educational resources, fund research, and collaborate with physicians.

GLOBAL PHYSICIAN IMPACT

- Led a panel on Advanced RCC management in Argentina, Uruguay, and Korea
- Attendees from 25 countries represented at IKCS: NA and IKCS: EU
- New engagements with five urology societies from Latin America, Europe, the Middle East, and Asia

GLOBAL PATIENT IMPACT

- We assisted 12 people internationally through our Patient Navigator Program
- Wilms Cancer Foundation (Canada) became a KCA Affiliate
- We are active members of the International Kidney Cancer Coalition, representing the KCA and US kidney cancer patients at their meeting in Buenos Aires, Argentina
- Virtual kidney cancer education through our online resources remains high

INTERNATIONAL AwarDEES

- Dr. Robert Jones, Scotland Keynote Speaker IKCS: EU
- Dr. Arnaud Mejean, France Fitzpatrick Award IKCS: EU
- Gemma E. Davies, BSc, MSc, United Kingdom 1st place abstract merit award IKCS: NA
In 2023 we awarded 6 innovative researchers a total of $412,500 in research funding. In the past 5 years we have impacted 32 research projects for a total of $4.9M.

The KCA welcomed six kidney cancer-focused organizations as Affiliate Partners. The KCA’s Affiliate Partner program expands the support networks available to people impacted by kidney cancer and allows for strategic collaborations to make advances in research, advocacy, and education.

**CHRIS “CJ” JOHNSON FOUNDATION**
- In contact with 23 patients who are living with renal medullary carcinoma (RMC)
- Remained in contact with 16 families that have lost loved ones to RMC
- Donated $10,000 to individuals diagnosed with RMC
- Saw 250 people participate in our in-person 5K Keepin’ It Renal event and 150 participate virtually from around the world including Greece, Colombia, Canada, the UK (Ricky Casey Trust Foundation) and the USA The KCA served as a silver sponsor again

**CHROMOPHobe ANd oNOCYtIC TUMOR ALLIANCE**
- Raised $34,700+ for research
- Was supported by 10 businesses “Going Orange” for kidney cancer awareness month
- Partnered with Pattern.org to allow patients to donate their tissue/tumors to research

**HLRCC FOUNDATION**
- Impacted more than 1,100 patients and families affected by HLRCC through various outlets
- Raised approximately $3,000 for research and other activities
- Spoke at IKCS to increase knowledge of and attention to HLRCC among healthcare providers
- Reached nearly 1,200 patients and families on social media

**JOEY’S WINGS**
- Raised $56,000 for research
- Donated $87,500 to translocation renal cell carcinoma research, including partnership with the KCA’s grant
- Co-hosted the Inaugural International Symposium of Translocation Renal Cell Carcinoma
- Financial support given to 22 pediatric kidney cancer families ($1,000/family)
JUDY NICHOLSON FOUNDATION

- Held 2nd Regional Symposium in Chicago and gained substantial traction, amassing 33,000 views and significantly surpassing average viewership
- Instagram audience expanded by 50%
- Hosted Joel Stern’s Virtual “JNF Patient Open Forum” to share experiences and find mutual understanding while navigating the challenges of a kidney cancer diagnosis. Average of 30–50 kidney cancer patients for each monthly gathering
- Held the JNF “Celebrate Life Dinner” on September 22nd which brought together over 50 patients and caregivers from the USA and Canada, representing diverse stages and subtypes of RCC. Hosted in San Antonio, TX, the event encouraged direct interactions between patients and various KCA affiliates, including COA, Joey’s Wings Foundation, KCCURE, ThriveWell, and others

THE WILMS CANCER FOUNDATION

- Concluded stage-one initiation of first AI-driven genomic research study into Nephroblastoma (Wilms)
- Shortlisted designation as a “Non-State Actor” by the WHO to provide specialist guidance (to WHO) in the fight against pediatric renal cancer
- Initiated operational launch of key financial support program at 10 sites across eight Sub-Saharan Africa countries

Thank you to our affiliates for representing the KCA as we continue to unlock the cure for kidney cancer together. To learn more about our affiliates visit their websites:

chrisjohnsonfoundation.org  
kidneycoa.org  
chriscjfoundation.org  
joeywings.org  
jnfkidneycancer.org  
wilmsfoundation.org  
hlrcinfo.org
THE KCA IS
ALL OF YOU
# Financials

## TOTAL EXPENSES

<table>
<thead>
<tr>
<th>Category</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education Programs</td>
<td>$1,526,800</td>
</tr>
<tr>
<td>Patient Programs</td>
<td>$764,500</td>
</tr>
<tr>
<td>General and Administrative</td>
<td>$717,800</td>
</tr>
<tr>
<td>Research Programs</td>
<td>$699,900</td>
</tr>
<tr>
<td>Public Awareness</td>
<td>$440,500</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$531,500</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$4,681,200</strong></td>
</tr>
</tbody>
</table>

## TOTAL REVENUE

<table>
<thead>
<tr>
<th>Category</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest and Investment</td>
<td>$1,528,300</td>
</tr>
<tr>
<td>Symposia</td>
<td>$1,751,500</td>
</tr>
<tr>
<td>Contributions</td>
<td>$968,200</td>
</tr>
<tr>
<td>Sponsorships and Grants</td>
<td>$385,600</td>
</tr>
<tr>
<td>Other</td>
<td>$109,800</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$4,744,000</strong></td>
</tr>
</tbody>
</table>

## ASSETS

<table>
<thead>
<tr>
<th>Current Assets</th>
<th>As of Oct 31, 2023</th>
<th>As of Oct 31, 2022 (PY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Bank Accounts</td>
<td>$1,562,700</td>
<td>$590,800</td>
</tr>
<tr>
<td>Total Accounts Receivable</td>
<td>-</td>
<td>$40,000</td>
</tr>
<tr>
<td>Total Other Current Assets</td>
<td>$21,582,200</td>
<td>$22,170,300</td>
</tr>
<tr>
<td>Total Current Assets</td>
<td>$23,144,900</td>
<td>$22,810,100</td>
</tr>
<tr>
<td>Total Fixed Assets</td>
<td>$8,100</td>
<td>$10,500</td>
</tr>
<tr>
<td>Total Other Assets</td>
<td>$493,300</td>
<td>$504,700</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$23,646,500</strong></td>
<td><strong>$23,316,300</strong></td>
</tr>
</tbody>
</table>

## LIABILITIES AND EQUITY

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>As of Oct 31, 2023</th>
<th>As of Oct 31, 2022 (PY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts/Grants Payable &amp; Accrued Expenses</td>
<td>$891,500</td>
<td>$834,300</td>
</tr>
<tr>
<td>Other Liabilities</td>
<td>$1,418,100</td>
<td>$1,205,400</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$2,309,600</td>
<td>$2,039,800</td>
</tr>
<tr>
<td>Total Equity</td>
<td>$21,338,800</td>
<td>$21,276,500</td>
</tr>
<tr>
<td><strong>Total Liabilities and Equity</strong></td>
<td><strong>$23,648,500</strong></td>
<td><strong>$23,316,300</strong></td>
</tr>
</tbody>
</table>
Our Mission and Vision

Our Mission
is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

Our Vision
is to be the universal leader in finding the cure for kidney cancer.

The Kidney Cancer Association (KCA) was founded in 1990 by a small group of patients and doctors in Chicago, Illinois, and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposia and a robust grant program, participates in legislative advocacy, and seeks to be the trusted source of education and resources for patients, caregivers, and all those impacted by kidney cancer.

Kidney Cancer Facts

- **77%**
  5-year Relative Survival Rate (2012–2018)

- **14,890**
  Estimated deaths in the US in 2023

- **81,800**
  Estimated number of new diagnosed cases in the US in 2023

- **628,355**
  Number of people living with kidney and renal pelvis cancer

- **RCC**
  2/3 of RCC cases are diagnosed early (stage I or II)

- **75%**
  of kidney cancer diagnoses are Clear Cell RCC

- Kidney cancer is more common in African Americans and American Indian/Alaska Natives

- Types of RCC:
  Clear Cell, Papillary, Chromophobe, Collecting Duct, Renal Medullary Carcinoma, Translocation, Unclassified

*Key Statistics about Kidney Cancer, American Cancer Society, 2023*
Who We Are

KCA STAFF
Gretchen E. Vaughan
President & CEO
Houston, Texas

Kendall Monroe
Chief Advancement Officer
Houston, Texas

Dr. Salvatore La Rosa
Chief Scientific Officer
New York, New York

LaRanda Burke
Chief Financial and Operating Officer
Houston, Texas

Susan Alanis
Director of Gift Operations
Houston, Texas

Christina Bargas
Manager, Events and Education
Denver, Colorado

Ryan Cerezo
Development Manager
Lathrop, California

Radha Chitale
Senior Director of Communications
Washington, D.C.

Rosemary Chustak
Patient Liaison
Milwaukee, Wisconsin

Christine Kelly-Weaver
Executive Assistant to the President and CEO
Houston, Texas

Melissa Lopez
Gift Operations Associate
Houston, Texas

Amy Marbaugh
Director of Patient Programs
Cleveland, Ohio

Emely Rodriguez
Accountant
Houston, Texas

Stephanie Shirley
Director of Advancement Services
Harrisburg, Pennsylvania

Jeanette Stensgaard
Senior Director of Events and Education
Aurora, Colorado

Sarah Tuck
Program Manager
Langhorne, Pennsylvania

Maggie Valdes
Manager of Corporate Partnerships
Houston, Texas

Angela Washington
Director of Operations
Houston, Texas

BOARD OF DIRECTORS
Gretchen E. Vaughan, President and CEO
Bradley C. Leibovich, MD (Chair)
Noah Buntman (Treasurer)
Joel Stern (Secretary)
Laurence Albiges, MD, PhD
Mahul B. Amin, MD
Ronald M. Bukowski, MD
Tessa Churchill, MD, MBA
Craig DePriester
Daniel J. George, MD
Jamie Graves
Ryan Natzke
David Perry, Esq.
Shelley Robson
Brian Shuch, MD
Laura Wood, RN, MSN, OCN
Ruben Ybarra

MEDICAL STEERING COMMITTEE
Daniel J. George, MD (Chair)
Brian Rini, MD (Vice Chair)
Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
Matthew Campbell, MD, MS
Jose A. Karam, MD, FACS
Bradley C. Leibovich, MD
Pavlos Msaouel, MD, PhD
Sumanta Pal, MD
Thomas Powles, MBBS, MRCP, MD
Sarah Psutka, MD
W. Kimryn Rathmell, MD, PhD
Eric Singer, MD, MA, MS, FACS, FASCO
Walter M. Stadler, MD, FACP (Emeritus)
Nizar M. Tannir, MD, FACP (Emeritus)
Tian Zhang, MD

CLINICAL ADVISORY BOARD
Laura S. Wood, RN, MSN, OCN (Chair)
Nancy Moldawer, RN, MSN (Co-Chair)
Nancy Ainslie, RN, BSN
Julia Batten, APRN, MSN, MPH
Patricia Fischer RN, MSN, OCN
Jan Jackson, RN
Zita Lim, PA-C
Virginia J. Seery, MSN, RN, ANP-BC
Julia Stevens, PharmD, BCOP
Kiran Virdee, RN, BSN, CCRN
Emily Wang, PharmD, BCOP

PATIENT & CAREGIVER ADVISORY COUNCIL
Ryan Natzke (Chair)
Kathleen Campbell
Steven Edwards
John Ferrell
Bruce Hill
Susan Hill
Vineeta Hiranandani
Ritchie Johnson
Benjamin Lundin
Matt McClain
Annamaria Scaccia
Cludia Tatum
Mariissa Willis
Salina Witt
Peggy Zuckerman
As we reflect on 2023 at the KCA, there is one word that seems to encapsulate our year the most: collaboration. This year, more than ever, we’ve witnessed the strength of unity within the KCA and kidney cancer community. Our shared vision and collective efforts have been pivotal in extending our reach and deepening our impact.

The cornerstone of our collaborative spirit was the launch of our new Affiliate Program. We welcomed six remarkable patient-focused organizations into our fold. This expansion is not just about numbers; it’s about the people behind these organizations joining together in a common cause. Together, we have broadened our horizons to reach more patients, amplify our voice, and unify in our mission to conquer kidney cancer.

Our partnerships have also allowed us to amplify voices that offer resources and hope. We’ve seen firsthand how collaboration can transcend barriers and magnify efforts toward a shared goal. So many of you in our community have contributed to amazing work through cooperation and mutual support.

As I look back on this year, I am filled with immense gratitude and pride for so much. The KCA’s journey is a testament to what can be achieved when we come together, combining our strengths and visions. And while we have accomplished much, we look down the road at how much more we still need to do. With your support, we’re determined to conquer what’s ahead.

Thank you for being an integral part of this journey. Together, we are stronger, louder, and closer to a world free of kidney cancer. Together, we are unstoppable.

With heartfelt thanks,

Gretchen E. Vaughan
President and CEO, Kidney Cancer Association
2023 has been a testament to the relentless need for advancements in kidney cancer research. At the KCA, we stand as the largest organization solely dedicated to bridging the gaps in kidney cancer research and treatment. This year, we’ve reinforced our commitment to making significant strides in this field.

Our focus has always been clear: to accelerate research breakthroughs and improve patient outcomes. The biggest strides in kidney cancer research and treatment are only possible through collaborative efforts. The KCA has been at the forefront, bringing together the brightest minds and the most passionate hearts in this quest.

Our role as the premier organization in this field comes with a great responsibility: to nurture and foster collaboration among researchers, clinicians, patients, and advocates. We have seen the power of collective effort in driving progress and innovation. It is through our united efforts that we can confront the challenges of kidney cancer, pushing the boundaries of what is possible. We saw this in 2023 through the phenomenal research that was funded.

As we look toward the future, our resolve is stronger than ever. The path ahead is filled with potential, and it is through our collaborative spirit that we will continue to make monumental advances in kidney cancer research.

Thank you for joining us in this vital mission.

With determination and hope,

Bradley Leibovich

Dr. Bradley C. Leibovich
Board Chair, Kidney Cancer Association
The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer.

MORE ONLINE RESOURCES
kidneycancer.org

KIDNEycANCER.ORG
office@kidneycancer.org | 800-850-9132

MAILING ADDRESS
2777 Allen Parkway Suite 424
Houston, TX 77019

DONATION ADDRESS
PO Box 676226
Dallas, TX 75267-6226

HQ IN HOUSTON TEXAS

@KidneyCancer | #UnstoppableTogether

MORE ONLINE RESOURCES
kidneycancer.org